An open randomized controlled study of topical B blocker gel for the treatment of infantile hemangioma: Comparison of safety and efficacy among topical 0%, 1% 5% B blocker gel.

An open randomized controlled study of topical B blocker gel for the treatment of infantile hemangioma: Comparison of safety and efficacy among topical 0%, 1% 5% B blocker gel. - A controlled study of B blocker gel for the treatment of infantile hemangioma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017148

Enrollment

Registered

2015-07-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile hemangioma

Interventions

Small amount of 0% B blockre gel is applied to tumor two times a day for 6 months. Small amount of 1% B blockre gel is applied to tumor two times a day for 6 months. Small amount of 5% B blockre gel i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: two types of infantile hemangioma (superficial type, mixed type which is both superficial and deep)

Exclusion criteria

Exclusion criteria: Patients who have asthma, cardiovascular malformation, diabetes, medication (including adrenaline, beta-blocker, calcium antagonist agent, digitalis product, CYP2D6 inhibitor), other skin disease, many infant hemangioma, congenital hemangioma. Patients who are ruled unfit to this study.

Design outcomes

Primary

Measure	Time frame
color of tumor	—

Countries

Japan

Contacts

Public ContactNaoaki Rikihisa

Chiba rosai hospital plastic surgery

rikihisa@faculty.chiba-u.jp0436-74-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026